Table 2.
Comparison of serum CA19-9 and CEA levels in patients with cholangiocarcinoma and benign biliary diseases
| CA19-9△ | CA19-9 | CEA | CA19-9 or CEA | CA19-9 and CEA | |
| Sensitivity(true positive)* | 65.71%(23/35) | 77.14%(27/35)a | 68.57%(24/35) | 91.43%(32/35) | 62.86%(22/35) |
| Specificity(true negative)** | 88.04%(81/92) | 84.78%(78/92) | 81.52%(75/92) | 76.09%(70/92) | 86.96%(80/92) |
| Positive predictive value | 67.65%(23/34) | 65.85%(27/41) | 58.54%(24/41) | 59.26%(32/54) | 64.71%(22/34) |
| Negative predictive value | 87.10%(81/93) | 90.70%(78/86) | 87.21%(75/86) | 95.89%(70/73) | 88.89%(80/90) |
| Accuracy | 81.89%(104/127) | 82.68%(105/127) | 77.95%(99/127) | 80.31%(102/127) | 80.31%(102/127) |
| False positive rate | 11.98%(11/92) | 15.22%(14/92) | 18.48%(17/92) | 23.91%(22/92) | 13.04%(12/92) |
*Number of positive tests/number of patients with cholangiocarcinoma. **Number of negative tests/number of patients with benign biliary diseases.
a
P < 0.05 vs CEA. △When the cutoff value of serum CA19-9 was 100 KU·L-1